Anti-CTLA-4 drugs, such as ipilimumab and tremelimumab, have not been approved in the treatment of patients with breast cancer, but there are many ongoing trials investigating the therapeutic role of ipilimumab in breast cancer. This evidence concerns the gene CTLA4 and breast carcinoma.